

Ronald J Gurrera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/788841/publications.pdf>

Version: 2024-02-01

27
papers

859
citations

567281

15
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

915
citing authors

#	ARTICLE	IF	CITATIONS
1	An International Consensus Study of Neuroleptic Malignant Syndrome Diagnostic Criteria Using the Delphi Method. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1222-1228.	2.2	160
2	Capacity to Consent to Treatment: Empirical Comparison of Three Instruments in Older Adults With and Without Dementia. <i>Gerontologist</i> , The, 2004, 44, 166-175.	3.9	132
3	Personality Traits in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2000, 188, 31-35.	1.0	92
4	Neuropsychological predictors of decision-making capacity over 9 months in mild-to-moderate dementia. <i>Journal of General Internal Medicine</i> , 2006, 21, 78-83.	2.6	89
5	Auditory P3 indexes personality traits and cognitive function in healthy men and women. <i>Psychiatry Research</i> , 2005, 133, 215-228.	3.3	39
6	A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 67-71.	1.4	38
7	Agreement Between Instruments for Rating Treatment Decisional Capacity. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 168-173.	1.2	32
8	The uncinate fasciculus and extraversion in schizotypal personality disorder: A diffusion tensor imaging study. <i>Schizophrenia Research</i> , 2007, 90, 360-362.	2.0	29
9	Recognizing psychiatric presentations of anti-NMDA receptor encephalitis in children and adolescents: A synthesis of published reports. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 262-268.	1.8	27
10	The five-factor model in schizotypal personality disorder. <i>Schizophrenia Research</i> , 2005, 80, 243-251.	2.0	25
11	Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. <i>Comprehensive Psychiatry</i> , 2007, 48, 205-211.	3.1	25
12	A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 398-408.	4.5	24
13	Personality Differences in Schizophrenia Are Related to Performance on Neuropsychological Tasks. <i>Journal of Nervous and Mental Disease</i> , 2005, 193, 714-721.	1.0	23
14	Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 423-441.	4.5	23
15	Potentially fatal outcomes associated with clozapine. <i>Schizophrenia Research</i> , 2018, 199, 386-389.	2.0	21
16	Cognitive task performance and symptoms contribute to personality abnormalities in first hospitalized schizophrenia. <i>Journal of Psychiatric Research</i> , 2014, 55, 68-76.	3.1	15
17	Aspiration Pneumonia. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 174-176.	1.4	14
18	Frequency and temporal sequence of clinical features in adults with anti-NMDA receptor encephalitis presenting with psychiatric symptoms. <i>Psychological Medicine</i> , 2019, 49, 2709-2716.	4.5	11

#	ARTICLE	IF	CITATIONS
19	Neuropsychological Performance Within-Person Variability Is Associated with Reduced Treatment Consent Capacity. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1200-1209.	1.2	8
20	Clozapine-Associated Aspiration Pneumonia: Case Series and Review of the Literature: Reply. <i>Psychosomatics</i> , 2019, 60, 103.	2.5	8
21	Preparing Residents in Training to Become Health-Care Leaders: A Pilot Project. <i>Academic Psychiatry</i> , 2014, 38, 701-705.	0.9	7
22	Hopes and Cautions for Instrument-Based Evaluation of Consent Capacity: Results of a Construct Validity Study of Three Instruments. <i>Ethics, Law and Aging Review</i> , 2004, 10, .	0.0	6
23	Meloxicam-desmopressin drug-drug interaction producing hyponatremia. <i>Psychiatry Research</i> , 2019, 279, 284-286.	3.3	4
24	A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2013, , 1.	1.4	3
25	Neuroleptic malignant syndrome controversies revisited—what is the incidence of neuroleptic malignant syndrome?. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 659-659.	1.9	2
26	A COMMENTARY ON IMPROVING CLOZAPINE ACCESSIBILITY AND REDUCING TREATMENT COST. <i>Psychiatry Research</i> , 2021, 296, 113644.	3.3	2
27	Treatment Bed Utilization Following Placement in a Foster Care Program for Veterans with Serious Mental Illness. <i>Community Mental Health Journal</i> , 2021, 57, 1442-1448.	2.0	0